Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01340651 · ClinicalTrials.gov registry record · Phase 2

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

A Phase 2 study of Myelofibrosis, sponsored by Incyte Corporation.

Completed
Registry status
Phase 2
Development phase
41
Enrollment target
3
Study locations

NCT01340651 is a Phase 2 study of Myelofibrosis that has completed, run by Incyte Corporation. The registered enrollment target is 41 participants, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (79% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01340651, a Phase 2 study of Myelofibrosis, has completed, sponsored by Incyte Corporation.

COMPLETED
Registry status
Phase 2
Development phase
41 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to determine the safety and tolerability of ruxolitinib (INCB018424) sustained release (SR) formulation in participants with primary myelofibrosis (PMF), post-polycythemia vera MF (PPV-MF), and post-essential thrombocythemia MF (PET-MF).

Conditions Studied

Myelofibrosis

Interventions

  • DRUG Ruxolitinib

Study Locations (3)

Arizona

  • - Scottsdale

Florida

  • - Winter Park

Texas

  • - Houston

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2011-03
Est. Completion 2012-07
Phase Phase 2

Sponsor

Incyte Corporation

239 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01340651

The ClinicalTrials.gov registry entry for NCT01340651 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (79% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib is the first listed.

NCT01340651 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT01340651 about?

NCT01340651 is a clinical study titled "Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients". The purpose of this study is to determine the safety and tolerability of ruxolitinib (INCB018424) sustained release (SR) formulation in participants with primary myelofibrosis (PMF), post-polycythemia vera MF (PPV-MF), and post-essential thrombocythemia MF (PET-MF).

What is the current status of trial NCT01340651?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2011-03. Estimated completion is 2012-07.

What conditions does trial NCT01340651 study?

This clinical trial studies the following conditions: Myelofibrosis.

What interventions are being tested in trial NCT01340651?

The interventions under investigation include: Ruxolitinib (DRUG).

Who is sponsoring clinical trial NCT01340651?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01340651 being conducted?

This trial has 3 study locations across Arizona, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myelofibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myelofibrosis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.